Annual Report on Form 20-F

Size: px
Start display at page:

Download "Annual Report on Form 20-F"

Transcription

1 Annual Report on Form 20-F

2 2 Teva at a Glance Founded in 1901 by three young pharmacists, today Teva Pharmaceutical Industries Ltd. is a leader in the global pharmaceutical industry, providing medicines essential to people s health all over the world. 1 out of every 7 prescriptions in the United States and 1 out of every 6 prescriptions in the U.K. is filled with a Teva product. Ranks among the top 10 pharmaceutical companies in the world The largest global producer of generic medicines Established specialty medicines business Operates in 60 countries, and distributes products all over the world Approximately 45,000 employees 64 billion tablets and capsules manufactured in 55,000+ product variants 1,000 molecules Chairman Dr. Phillip Frost President & CEO Erez Vigodman Web address NYSE ticker TEVA

3 3 Financial Highlights Amounts in millions of U.S. dollars except per share amounts Net revenues 20,314 20,317 18,312 16,121 13,899 Gross profit GAAP 10,707 10,652 9,515 9,065 7,367 Gross profit NON GAAP* 11,895 12,071 10,705 9,669 8,119 Operating income - GAAP 1,649 2,205 3,109 3,871 2,405 Operating income - NON GAAP* 5,198 5,715 5,253 4,933 3,853 Net income attributable to Teva - GAAP Net income attributable to Teva - NON GAAP* Earnings per share attributable to Teva - GAAP Diluted ($) Earnings per share attributable to Teva - NON GAAP* Diluted ($) 1,269 1,963 2,759 3,331 2,000 4,255 4,671 4,438 4,134 3, * See non GAAP reconciliation beginning on page 79 of our Annual Report on Form 20 - F Dividends per share in the past 5 years* * According to USD/NIS exchange rate in Feb $0.91 $1.14 $ $ $0.68 Net revenues Other* 10% Generics 49% ROW** 19% US 52% by segment by markets Specialty 41% Europe* 29% * Other activities include our OTC business with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices * All members of the European Union, Switzerland, Norway, Albania and the countries of former Yugoslavia. ** Primarily Japan, Canada, Latin America, Israel and Russia

4 Our Business Generics Specialty Chemical and therapeutic equivalents of originator pharmaceuticals in a variety of dosage forms: tablets, capsules, ointments, creams, liquids, injectables and inhalants. Strong innovation power focused on key therapeutic areas such as central nervous system (CNS), respiratory and oncology. NTEs New Therapeutic Entities - known molecules that are formulated, delivered or used in a novel way to address unmet patient needs. API Active Pharmaceutical Ingredients Integrated R&D Generic and Specialty R&D TGO - Teva Global Operations OTC Over-the-counter medicine joint venture with P&G

5 5 Generics Teva is the number 1 generics company in the world, providing affordable access to medicines for patients and healthcare systems. Leader in the U.S. Leader in Europe Leader in Canada No. 3 in Japan Generics net revenues $9.9 B US 42% ROW 23% Generics net revenues by markets Europe 35% A broad range of basic chemical entities and specialized product families such as sterile products, hormones, narcotics, high-potency drugs and cytotoxic substances More than 400 generic products approved in the U.S. and over 1,000 approved in Europe A leader in quality manufacturing of generics, with state-of-the-art facilities using advanced testing equipment Moving Forward Complex Generics We seek to establish leadership in high-value generics through coordinated global R&D activities, both by pursuing first-to-market opportunities and by developing complex generic products. We will augment our commercial growth strategy in generics with our R&D capabilities in order to sustain our advantages in complex oral and inhalation delivery methods and grow our capabilities in other complex technologies, such as injectables, liposomal drug delivery, long-acting release and others. API Our generics business also includes our world leading API (Active Pharmaceutical Ingredients) manufacturing business - the ingredients that provide the drug with its therapeutic activity. API sales to third parties $692 M We have operations around the globe, producing approximately 300 APIs in many therapeutic areas We produce APIs not only for our own use but also for many other pharmaceutical companies

6 6 Specialty We have a focused and robust global specialty pharmaceutical business Our specialty business focuses on several core franchises, most significantly medicines for central nervous system (CNS) disorders (with a strong emphasis on multiple sclerosis - MS, neurodegenerative disorders, and pain) and respiratory medicines, as well as other areas such as oncology and women s health. Specialty net revenues $8.4 B Europe 20% ROW 8% Specialty revenues by market US 72% Women s health 5% Respiratory 11% Oncology 12% Other specialty 7% Specialty by therapeutic areas CNS 65% We are expanding our pipeline and portfolio in therapeutic areas where we have significant market presence, infrastructure, patient support and know-how In CNS, we have a strong legacy with Copaxone, the leading global treatment for relapsing-remitting multiple sclerosis. In January 2014, the FDA approved Copaxone 40 mg/ml. This formulation will allow for a more convenient dosing regimen of only three times a week Teva global specialty R&D focuses on development of novel specialty products in our key therapeutic areas of CNS and respiratory, with select projects in additional areas, to address unmet patient needs Moving Forward Our strategy is based on building our portfolio and pipeline in therapeutic areas where we have demonstrated strengths, and expanding our presence in related areas through strategic partnerships Our Leading brands CNS Copaxone for relapsing remitting multiple sclerosis Azilect for Parkinson s disease Nuvigil for sleep disorders Oncology Treanda for certain hematological cancers Various biologics for support of cancer patients Respiratory QVAR for the treatment of asthma ProAir HFA, the leading quick relief inhaler for bronchospasm Women s Health Comprehensive portfolio of contraceptive products and others

7 7 OTC - Over the Counter PGT Healthcare - a winning partnership with a world leader - Procter & Gamble PGT in-market sales $1.5 B PGT Healthcare has recorded year over year double-digit growth since its establishment, ahead of the overall OTC market A unique collaboration which combines the core technology and go-to-market strengths of Teva with the consumer understanding and branding strengths of P&G, to develop and commercialize branded OTC medicines Includes the branded OTC medicines of the two companies in categories such as cough/cold and allergy, digestive wellness, vitamins, minerals and supplements (VMS) & analgesics Operates in all markets outside North America, in more than 65 countries New Therapeutic Entities (NTEs) Leveraging our strong capabilities in generics and specialty R&D, Teva is building its NTE development program into a major growth engine for the company Through the NTE program, we are developing late-stage products from known molecules that offer important improvements for patients These advances can lead to better adherence, lower costs and ultimately, better health outcomes To date, we have 14 new NTE products in development, including: > Four abuse deterrent tablets for the treatment of pain > Long-acting injections for the treatment of schizophrenia > Four fixed-dose combinations for the treatment of HIV 250 formulators Teva is unique GENERIC R&D Preclinical development 1000 product files Clinical development 15 complex tech. Global regulatory Proprietary tech. Therapeutic areas knowledge Injectable device dev. SPECIALTY R&D Unprecedented scale Integration of established generic and specialty skills Disciplined process Dedicated resources Combining technological and drug development capabilities in a unique integrated R&D organization

8 8 Teva Global Integrated R&D Our integrated generic and specialty R&D organization is one of our primary competitive advantages Generic R&D Capabilities in a wide range of dosage forms and therapeutic areas as well as in specialized product families and technologies Specialty R&D Clinical development strengths and ability to identify unmet medical needs Maximize our ability to identify and act upon new opportunities Our specialty pipeline Selected pipeline products in clinical development, by therapeutic area and stage: Approved Submitted Phase III Phase II Phase I CNS Respiratory Oncology Women s health Cardiovascular Others

9 9 Teva Global Operations In, Teva produced approximately 64 billion tablets & capsules and over 700 million sterile units We operate 50 pharmaceutical plants in North America, Europe, Latin America, Asia and Israel, with two additional sites currently under construction These plants manufacture solid dosage forms, sterile injectables, liquids, semi-solids, inhalers and medical devices Our two primary manufacturing technologies, solid dosage forms and injectables, are available in North America, Latin America, Europe and Israel In December 2012, we announced a cost reduction program intended to result in $2 billion of savings by the end of We are focusing particular attention on improving our procurement systems by leveraging our purchasing power and improving our production network, supply chain, and resources deployment processes

10 Our markets Teva has evolved into a truly global powerhouse. We operate in 60 countries, and distribute our products all over the world. United States Europe ROW United States net revenues $10.4 B Europe net revenues $6.0 B ROW net revenues $3.9 B Specialty 58% Other 2% Generics 40% Generics 58% Other 14% Specialty 28% Other 25% Specialty 17% by business by business by business Generics 58%

11

12 Investor Relations Kevin Mannix VP, Head of Global Investor Relations Tel: +1 (215) Tomer Amitai Senior Director, Investor Relations Tel: +972 (3) Pharmaceutical Industries Ltd. Corporate Communications Iris Beck Codner SVP, Chief Communications Officer Tel: +972 (3) Corporate Headquarters 5 Basel St., P.O.Box 3190 Petach Tikva , Israel Tel: +972 (3) Fax: +972 (3)

Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited Contents Teva at a Glance 4 President and Chief Executive Officer s Letter to Shareholders 6 Financial Highlights 10 Business Overview 12 Global Reach 16 Leadership

More information

An integrated global healthcare company

An integrated global healthcare company An integrated global healthcare company 1 A Mission to create healthier communities globally Zydus Cadila is dedicated to life In all its dimensions. Our world is shaped by a passion for innovation, commitment

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2011

More information

TEVA REITERATES COMMITMENT TO CASH-AND-STOCK ACQUISITION OF MYLAN FOR $82.00 PER SHARE

TEVA REITERATES COMMITMENT TO CASH-AND-STOCK ACQUISITION OF MYLAN FOR $82.00 PER SHARE TEVA REITERATES COMMITMENT TO CASH-AND-STOCK ACQUISITION OF MYLAN FOR $82.00 PER SHARE Provides Significant Premium and Immediate Value for Mylan Stockholders and Opportunity to Participate in Upside Potential

More information

INNOVATING FOR BETTER HEALTH

INNOVATING FOR BETTER HEALTH TEVA PHARMACEUTICAL INDUSTRIES LTD 1 INNOVATING FOR BETTER HEALTH TEVA GLOBAL CORPORATE SOCIAL RESPONSIBILITY HIGHLIGHTS Pharmaceutical Industries Ltd. TEVA PHARMACEUTICAL INDUSTRIES LTD 2 CONTENTS LETTER

More information

Dr. Reddy s Q3 and 9M FY16 Financial Results

Dr. Reddy s Q3 and 9M FY16 Financial Results Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CONTACT

More information

Teva and Checkpoint Therapeutics Announce License Agreement for Oral PARP Inhibitor

Teva and Checkpoint Therapeutics Announce License Agreement for Oral PARP Inhibitor Teva and Checkpoint Therapeutics Announce License Agreement f Oral PARP Inhibit Checkpoint to Obtain Exclusive Wldwide Development and Commercialization Rights Jerusalem and New Yk, NY, January 7, 2016

More information

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies NEC3-52 November 2014 Contents

More information

Innovating for Better Health

Innovating for Better Health Innovating for Better Health Table of contents ABOUT TEVA Teva at a glance Message from our President and CEO: Erez Vigodman Citizenship at Teva 2014 citizenship highlights 3 3 5 6 7 A European perspective

More information

PHARMACY TECHNICIAN COURSE DESCRIPTIONS

PHARMACY TECHNICIAN COURSE DESCRIPTIONS PHARMACY TECHNICIAN COURSE DESCRIPTIONS OCCUPATIONAL COMPLETION POINTS AND PROGRAM LENGTH: * Basic Healthcare Worker OCP A 90 Hours (COURSE #HSC 0003) * Community Pharmacy Technician OCP B 360 Hours (COURSE

More information

Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company

Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company PRESCRIPTION DRUG RIDER This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health

More information

Flamel Technologies Provides Update on Corporate Progress

Flamel Technologies Provides Update on Corporate Progress Flamel Technologies Provides Update on Corporate Progress Clinical Programs Continue to Move Forward Outlines Full Year 2016 Revenue Guidance Lyon, France January 8, 2016 - Flamel Technologies (NASDAQ:

More information

Endo Health Solutions Corporate Overview. September 12, 2012

Endo Health Solutions Corporate Overview. September 12, 2012 Endo Health Solutions Corporate Overview September 12, 2012 Endo Health Solutions and Its Companies Endo Pharmaceuticals Overview Endo Pharmaceuticals creates high-value branded products that address

More information

Richard T. Clark Chief Executive Officer and President. Executing on Our Strategy

Richard T. Clark Chief Executive Officer and President. Executing on Our Strategy Richard T. Clark Chief Executive Officer and President Executing on Our Strategy Merck s Plan to Win: Preparing for Our Future Success BECOME THE MOST TRUSTED INDUSTRY LEADER IN DELIVERING VALUE TO CUSTOMERS

More information

China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results

China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results HAIKOU CITY, China, August 10, 2010 China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ( China Pharma or the Company ), a leading fully

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September

More information

ACINO SWITZERLAND. Delivering Health Ensuring Effective Relief

ACINO SWITZERLAND. Delivering Health Ensuring Effective Relief ACINO SWITZERLAND Delivering Health Ensuring Effective Relief Content CEO Letter 03 Acino at a glance 05 Our brand»acino Switzerland«06 Commercial Operations 08 Out-licensing 10 Contract Manufacturing

More information

Brand Quality with Asian Advantages

Brand Quality with Asian Advantages Brand Quality with Asian Advantages ScinoPharm Taiwan, Ltd. No.1, Nan-Ke 8th Road, Tainan Science Park, Shan-Hua, Tainan, 74144, Taiwan TEL : 886-6-505-2888 FAX : 886-6-505-2898 Email Contact : mkt@scinopharm.com

More information

Prescription Drug Rider

Prescription Drug Rider Prescription Drug Rider This Rider is part of the Evidence of Coverage and is effective on the date Your group is effective or renews its coverage with Southern Health Services, Inc. Benefits are available

More information

The Future of Consumer Health Care

The Future of Consumer Health Care The Future of Consumer Health Care Coming Together To Lead The Consumer Health Care Industry 2 Creating a New Business Model in Consumer Health Care 3 Serve More Consumers In More Parts of the World, More

More information

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple

More information

RECIPHARM TAKES NEXT STEP TOWARDS GLOBAL LEADERSHIP 18 th April, 2016 Thomas Eldered, Jean-François Hilaire

RECIPHARM TAKES NEXT STEP TOWARDS GLOBAL LEADERSHIP 18 th April, 2016 Thomas Eldered, Jean-François Hilaire RECIPHARM TAKES NEXT STEP TOWARDS GLOBAL LEADERSHIP 18 th April, 2016 Thomas Eldered, Jean-François Hilaire 1 RECIPHARM TAKES NEXT STEP TOWARDS GLOBAL LEADERSHIP Another step change in reach and scale

More information

5/5/2015 PHARMACY WHAT S AN EMPLOYER TO DO? Current Structure Misaligned

5/5/2015 PHARMACY WHAT S AN EMPLOYER TO DO? Current Structure Misaligned PHARMACY WHAT S AN EMPLOYER TO DO? MAY 15, 2015 Debbie Doolittle Nashville, TN Pharmaceutical Spending Per Capita, 2013 vs. 2018 The US vs. the Rest of the World 1 Current Pharmacy Landscape How Did We

More information

Flamel Technologies Acquires FSC Pediatrics

Flamel Technologies Acquires FSC Pediatrics Flamel Technologies Acquires FSC Pediatrics Diversifies product portfolio and brings established commercial infrastructure Revised full year 2016 revenue guidance of $110 to $130 million Conference call

More information

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge

More information

Specialty Pharmacy. Business Plan. July 8, 2013. 2013 RUSH University Medical Center

Specialty Pharmacy. Business Plan. July 8, 2013. 2013 RUSH University Medical Center Specialty Pharmacy Business Plan July 8, 2013 Specialty Pharmaceuticals What are they? Biotech/gene-based therapy Require special handling Newer products oral or self- administered One third have REMS

More information

Prescription Drug Benefits

Prescription Drug Benefits Stryker s healthcare plan provides benefits for covered prescription drugs, including contraceptives, insulin and diabetic supplies. Benefits are paid for covered drugs that are medically necessary for

More information

The relationship between the Debrecen University and TEVA Pharmaceuticals Ltd. Prepared: by dr. Ildiko Mihok Head of Faculty 2013

The relationship between the Debrecen University and TEVA Pharmaceuticals Ltd. Prepared: by dr. Ildiko Mihok Head of Faculty 2013 The relationship between the Debrecen University and TEVA Pharmaceuticals Ltd. Prepared: by dr. Ildiko Mihok Head of Faculty 2013 1 The relationship between the Debrecen University and TEVA Pharmaceuticals

More information

Z E N T I VA AT G L A N C E. We a i m t o b e y o u r va l u e d ge n e r i c s partner

Z E N T I VA AT G L A N C E. We a i m t o b e y o u r va l u e d ge n e r i c s partner Z E N T I VA AT G L A N C E We a i m t o b e y o u r va l u e d ge n e r i c s partner Poland Czech Republic Germany United Kingdom France Portugal Switzerland Italy Slovenia Estonia Latvia Lithuania Slovakia

More information

Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of

Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of September 10, 2014 Contact: Shikha Virdi 905-919-0200 ext. 5504 EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston Data

More information

DPP - DSM in motion: driving focused growth DSM and JLL create leading pharma services company in US$ 2.6bn transaction 19 November 2013.

DPP - DSM in motion: driving focused growth DSM and JLL create leading pharma services company in US$ 2.6bn transaction 19 November 2013. DPP - DSM in motion: driving focused growth DSM and JLL create leading pharma services company in US$ 2.6bn transaction 19 November 2013 Page Safe harbor statement This presentation may contain forward-looking

More information

CAN-FITE BIOPHARMA LTD.

CAN-FITE BIOPHARMA LTD. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month

More information

From the Text. Definitions. Definitions. Definitions. Definitions. RSPT 2217 Basic Concepts & Principles. RSPT 2217-01 Basic Concepts

From the Text. Definitions. Definitions. Definitions. Definitions. RSPT 2217 Basic Concepts & Principles. RSPT 2217-01 Basic Concepts RSPT 2217 & Principles Gardenhire Chapter 1; p. 1-10 From the Text Key Terms and page 2 Orphan Drugs Table 1-1; page 6 Abbreviations Table 1-2; page 8 Aerosolized Agents Table 1-3; page 9 Drug: Pharmacology:

More information

EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston

EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston Erin-Marie Beals Phone 1-781-681-2850 September 9, 2014 EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston Data include

More information

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Fern Barkalow, Ph.D, Senior Analyst, Oncology Citeline One of the biggest challenges facing biosimilar drug developers is

More information

J.P. MORGAN HIGH YIELD & LEVERAGED FINANCE CONFERENCE FEBRUARY 24, 2015

J.P. MORGAN HIGH YIELD & LEVERAGED FINANCE CONFERENCE FEBRUARY 24, 2015 J.P. MORGAN HIGH YIELD & LEVERAGED FINANCE CONFERENCE FEBRUARY 24, 2015 DISCLAIMER This presentation contains, in addition to historical information, certain forward-looking statements within the meaning

More information

Medication Management: A Family Caregiver s Guide

Medication Management: A Family Caregiver s Guide Family Caregiver Guide Medication Management: A Family Caregiver s Guide Types of Medications You should make sure all of your family member s doctors and the home care nurse know all the overthe-counter

More information

全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report

全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report /wepdwukltuyot 全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report 联 系 购 买 电 话 :010-82863480 公 司 名 称 : 佐 思 信 息 公 司 地 址 : 北 京 市 海 淀 区 苏 州 街 18 号 院 长 远 天

More information

Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis

Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis May 25, 2015 Contact: Shikha Virdi 905-919-0200 ext. 5504 Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis Rebif now reimbursed under Ontario Drug Benefit Program

More information

Overview of the Specialty Drug Trend

Overview of the Specialty Drug Trend WHITE PAPER Overview of the Specialty Drug Trend Succeeding In The Rapidly Changing U.S. Specialty Market 1 Specialty drugs are prescribed to treat complex conditions such as cancer, HIV and inflammatory

More information

PHOTOCURE ASA BUILDING A SPECIALTY PHARMA COMPANY

PHOTOCURE ASA BUILDING A SPECIALTY PHARMA COMPANY PHOTOCURE ASA BUILDING A SPECIALTY PHARMA COMPANY RESULTS OF THE FIRST QUARTER 2013 25 April 2013 Kjetil Hestdal, MD, President & CEO Erik Dahl, CFO DISCLAIMER The information included in this Presentation

More information

Disclosure. This presentation contains forward-looking statements.

Disclosure. This presentation contains forward-looking statements. Disclosure This presentation contains forward-looking statements. These forward-looking statements are based on management's current expectations and assumptions as of the date of this presentation, and

More information

Pharmacy Technician Training Program. Minimum Competencies

Pharmacy Technician Training Program. Minimum Competencies 1. Pharmacy Practice Pharmacy Technician Training Program Minimum Competencies 1.1 The candidate shall be familiar with the mission of pharmacy and the various permitted pharmacy practice sites. The candidate

More information

Global Market Study on Compounding Pharmacies: Regulatory Harmonization and Innovative Therapeutic Areas to Boost Demand for Compounded Drugs

Global Market Study on Compounding Pharmacies: Regulatory Harmonization and Innovative Therapeutic Areas to Boost Demand for Compounded Drugs Brochure More information from http://www.researchandmarkets.com/reports/3496119/ Global Market Study on Compounding Pharmacies: Regulatory Harmonization and Innovative Therapeutic Areas to Boost Demand

More information

2007 Bear Stearns 20 th Annual Healthcare Conference. New York, New York September 11, 2007

2007 Bear Stearns 20 th Annual Healthcare Conference. New York, New York September 11, 2007 2007 Bear Stearns 20 th Annual Healthcare Conference New York, New York September 11, 2007 John Hammergren Chairman and Chief Executive Officer Safe Harbor Clause Some of the information in this presentation

More information

Introduction to Enteris BioPharma

Introduction to Enteris BioPharma Introduction to Enteris BioPharma Enteris BioPharma Intelligent Solutions for Oral Drug Delivery Privately held, New Jersey based biotech company Owned solely by Victory Park Capital, a large Chicago based

More information

Guidance for Industry Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator,

Guidance for Industry Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator, Reprinted from FDA s website by Guidance for Industry Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator, Guidance And Antiasthmatic for Drug Industry Products for Over-the-Counter Labeling

More information

Primer: The Pharmaceutical Industry Han Zhong l Updated June 2012

Primer: The Pharmaceutical Industry Han Zhong l Updated June 2012 Primer: The Pharmaceutical Industry Han Zhong l Updated June 2012 Introduction The pharmaceutical industry produces prescription and over-the-counter drugs as well as biologic products primarily intended

More information

RECORD OF COMMERCIAL SUCCESS

RECORD OF COMMERCIAL SUCCESS MULTIPLE SCLEROSIS HEMOPHILIA CD-20 THERAPIES RECORD OF COMMERCIAL SUCCESS 5 5 Note: Rituxan and Gazyva are in collaboration with Roche Revenues ($B) Non-GAAP Diluted EPS ($) +18% CAGR +24% CAGR 12.09

More information

Introduction to Sanofi and Genzyme

Introduction to Sanofi and Genzyme Introduction to Sanofi and Genzyme 495/MetroWest Partnership's Conference Panel December 15, 2015 Michelle Multiple Sclerosis Denmark Overview Who is Sanofi? Who is Genzyme MetroWest Investment Talent

More information

February 2014 Patient Savings Program Use Analysis

February 2014 Patient Savings Program Use Analysis Providing key policy setters and decision makers in the global health sector with unique and transformational insights into healthcare dynamics derived from granular analysis of information. February 2014

More information

STATS WINDOW. INDUSTRY REVIEW AT A GLANCE Global Pharmaceutical Industry

STATS WINDOW. INDUSTRY REVIEW AT A GLANCE Global Pharmaceutical Industry Volume 6, Issue 6, December 2013 STATS WINDOW The Pacific Business Review International has taken an initiative to start a section which will provide a snapshot of major Global & Indian economic indicators

More information

Medication Reconciliation Technician Standard Workflow

Medication Reconciliation Technician Standard Workflow Process Description: Medication Reconciliation is the process of making a good faith attempt to obtain a patients prior to admission medication history, which is eventually reconciled against a patients

More information

Most countries will experience an increase in pharmaceutical spending per capita by 2018

Most countries will experience an increase in pharmaceutical spending per capita by 2018 6 Most countries will experience an increase in pharmaceutical spending per capita by 218 Pharmaceutical spending per capita, 213 versus 218 1,6 1,4 Pharmaceutical Spend per Capita 1,2 1, 8 6 4 2 US Japan

More information

EDUCATOR S LESSON PLAN

EDUCATOR S LESSON PLAN EDUCATOR S LESSON PLAN Pharmacy Technician Training Program Student Version Orientation Orientation introduces the student to basic terms and definitions. An introduction to the Pharmacy Technician Certification

More information

Prescription Drug Plan

Prescription Drug Plan Prescription Drug Plan The prescription drug plan helps you pay for prescribed medications using either a retail pharmacy or the mail order program. For More Information Administrative details and procedures

More information

PharmaCare is BC s public drug insurance program that assists BC residents in paying for eligible prescription drugs and designated medical supplies.

PharmaCare is BC s public drug insurance program that assists BC residents in paying for eligible prescription drugs and designated medical supplies. PHARMANET AND PHARMACARE DATA DICTIONARY Date Range: September 1, 1995 to present date, data is provided by calendar year Data Source: BC Ministry of Health Description The PharmaNet system is an online,

More information

Trazodone For Pain Relief

Trazodone For Pain Relief Trazodone For Pain Relief 1 buy trazodone uk 2 trazodone weight gain forum 3 taking trazodone for pain 4 trazodone rxlist 5 trazodone lexapro 6 trazodone for anxiety daytime 7 getting high on trazodone

More information

Quality Affordable Healthcare Products. Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company July 31, 2013

Quality Affordable Healthcare Products. Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company July 31, 2013 Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company July 31, 2013 Important Information For Investors And Shareholders This announcement does not constitute an offer to sell, or

More information

Pharmaceuticals Production Services Boehringer Ingelheim. Our expertise in world-class contract manufacturing for your success

Pharmaceuticals Production Services Boehringer Ingelheim. Our expertise in world-class contract manufacturing for your success Pharmaceuticals Production Services Boehringer Ingelheim Our expertise in world-class contract manufacturing for your success Successful partnership Dr Wolfram Carius Head of Corporate Division Pharmaceuticals

More information

News Release. 1 December 2011. Consort Medical plc. Interim results for the six months ended 31 October 2011

News Release. 1 December 2011. Consort Medical plc. Interim results for the six months ended 31 October 2011 News Release 1 December 2011 Consort Medical plc Interim results for the six months ended 31 October 2011 Consort Medical plc delivers record first half revenues and profits. Consort Medical plc (LSE:

More information

Narcotic drugs used for pain treatment Version 4.3

Narcotic drugs used for pain treatment Version 4.3 Narcotic drugs used for pain treatment Version 4.3 Strategy to restrict the pack sizes or the type of packaging available in public pharmacies. 1. Introduction The document describing the strategy of the

More information

Multiple Sclerosis Treatment Market: Opportunities for Oral Drugs

Multiple Sclerosis Treatment Market: Opportunities for Oral Drugs Brochure More information from http://www.researchandmarkets.com/reports/706246/ Multiple Sclerosis Treatment Market: Opportunities for Oral Drugs Description: Only about 36% of Multiple Sclerosis (MS)

More information

Q3 2015 Financial Results and Corporate Update. November 4, 2015

Q3 2015 Financial Results and Corporate Update. November 4, 2015 Q3 2015 Financial Results and Corporate Update November 4, 2015 Introductions and Forward- Looking Statements Silvia Taylor, SVP Investor Relations and Corporate Affairs Agenda Introductions and Forward-Looking

More information

Flamel Technologies Announces Second Quarter Results of Fiscal Year 2015

Flamel Technologies Announces Second Quarter Results of Fiscal Year 2015 Flamel Technologies Announces Second Quarter Results of Fiscal Year 2015 Product revenue guidance for 2015 of $170-$185 million reaffirmed Conference call with management to take place at 10:00 am ET on

More information

OUTPATIENT PRESCRIPTION DRUG RIDER

OUTPATIENT PRESCRIPTION DRUG RIDER OUTPATIENT PRESCRIPTION DRUG RIDER This Rider is issued to the Policyholder on the Group Effective Date or Group Renewal Date and made a part of the Evidence of Coverage to which it is attached. In case

More information

NEW BRUNSWICK GRADUATION REQUIREMENTS PROGRAM OBJECTIVES PROGRAM OVERVIEW CAREER OPPORTUNITIES PREREQUISITES

NEW BRUNSWICK GRADUATION REQUIREMENTS PROGRAM OBJECTIVES PROGRAM OVERVIEW CAREER OPPORTUNITIES PREREQUISITES NEW BRUNSWICK *Please scroll to see other provinces. PHARMACY TECHNICIAN PROGRAM OBJECTIVES The Pharmacy Technician diploma program will provide the student with the required knowledge base and practical

More information

Multiple Sclerosis Treatments: World Market Outlook to 2011

Multiple Sclerosis Treatments: World Market Outlook to 2011 Brochure More information from http://www.researchandmarkets.com/reports/2860814/ Multiple Sclerosis Treatments: World Market Outlook to 2011 Description: Multiple sclerosis (MS) is a chronic demyelinating

More information

Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results

Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results FOR IMMEDIATE RELEASE Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results Holon, ISRAEL February 9, 2016 Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported

More information

Philips Healthcare overview. Steve Rusckowski CEO Philips Healthcare

Philips Healthcare overview. Steve Rusckowski CEO Philips Healthcare Philips Healthcare overview Steve Rusckowski CEO Philips Healthcare 1 Executive summary Exited 2010 with solid growth and strengthened operational performance as promised Grew faster than our markets,

More information

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies Greetings from Chicago! Beaches Yes! Pharma Beginnings! Bogota 1974 Selling Drugs in Colombia Global

More information

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q 2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements

More information

New Solutions for Sea Lice Control. Ian Thompson Head Global Technical Services, Aqua Pharmaceuticals

New Solutions for Sea Lice Control. Ian Thompson Head Global Technical Services, Aqua Pharmaceuticals New Solutions for Sea Lice Control Ian Thompson Head Global Technical Services, Aqua Pharmaceuticals Novartis is a world-leading healthcare company Leading market position One of 20 largest companies by

More information

Teva Respiratory Opportunity Business Update Meeting November 4, 2010

Teva Respiratory Opportunity Business Update Meeting November 4, 2010 Teva Respiratory Opportunity Business Update Meeting November 4, 2010 Forward Looking Statement This release contains forward-looking statements, which express the current beliefs and expectations of management.

More information

Recipharm creates a global CDMO leader through SEK 1.7 billion strategic acquisitions in the US, Sweden and India

Recipharm creates a global CDMO leader through SEK 1.7 billion strategic acquisitions in the US, Sweden and India Press release 18 th April 2016 Recipharm creates a global CDMO leader through SEK 1.7 billion strategic acquisitions in the US, Sweden and India Recipharm AB (publ) ( Recipharm or the Company ) announces

More information

Daiichi Sankyo to Acquire Ambit Biosciences

Daiichi Sankyo to Acquire Ambit Biosciences For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please

More information

Trazodone 150 Mg For Anxiety

Trazodone 150 Mg For Anxiety Trazodone 150 Mg For Anxiety trazodone 50 mg dose long term use of trazodone for insomnia 200 mg trazodone for sleep street value trazodone 100 mg can trazodone tablets be crushed long term use of trazodone

More information

Core therapeutic areas

Core therapeutic areas Core therapeutic areas Platforms for growth Luke Miels, Executive Vice President, Global Portfolio & Product Strategy and Corporate Affairs Current business is led by core therapeutic areas Sales 9M 2014

More information

The Swedish Drug Development Pipeline June 2012. A survey conducted by:

The Swedish Drug Development Pipeline June 2012. A survey conducted by: The Swedish Drug Development Pipeline June 2012 A survey conducted by: Key findings More companies report clinical trials There has been a increase in number of companies contributing with information

More information

PHARMACY TECHNICIAN CCAPP Accredited Program Provisional Status

PHARMACY TECHNICIAN CCAPP Accredited Program Provisional Status PHARMACY TECHNICIAN CCAPP Accredited Program Provisional Status Program Overview As a result of pharmacists taking a more active role in clinical drug therapy and the counselling of their patients, the

More information

Specialty Pharmacy? Disclosure. Objectives Technician

Specialty Pharmacy? Disclosure. Objectives Technician Disclosure What s so SPECIAL about? I have no actual or potential conflict of interest in relation to this program/presentation. Michael DeCoske, PharmD, BCPS Associate Chief Pharmacy Officer Duke University

More information

New Mid-Term Business Plan Sunrise 2012

New Mid-Term Business Plan Sunrise 2012 New Mid-Term Business Plan Sunrise 2012 CHUGAI PHARMACEUTICAL CO.,LTD. President and CEO Osamu Nagayama January 30/31, 2008 Forward Looking Statements This presentation may include forward looking statements

More information

Photocure ASA. Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO

Photocure ASA. Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO Brilliance in photodynamic technology TM Photocure ASA Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO Agreement with Salix

More information

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010 U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction

More information

Princeton University Prescription Drug Plan Summary Plan Description

Princeton University Prescription Drug Plan Summary Plan Description Princeton University Prescription Drug Plan Summary Plan Description Princeton University Prescription Drug Plan Summary Plan Description January 2015 Contents Introduction... 1 How the Plan Works... 2

More information

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

TEVA PHARMACEUTICAL INDUSTRIES LIMITED UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or È ANNUAL REPORT PURSUANT

More information

WuXi PharmaTech Announces Second-Quarter 2014 Results

WuXi PharmaTech Announces Second-Quarter 2014 Results WuXi PharmaTech Announces Second-Quarter 2014 Results SHANGHAI, August 13, 2014 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development services company serving

More information

Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA

Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA Media Release Basel, 28 June 2016 Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA OCREVUS is the first investigational medicine

More information

Enhancing Value With Financial & Operational Excellence

Enhancing Value With Financial & Operational Excellence Enhancing Value With Financial & Operational Excellence Robert Hombach CFO & COO Enhancing Value With Financial & Operational Excellence Growing Sales & Earnings Generating value in attractive markets

More information

The Cell Therapy Catapult

The Cell Therapy Catapult The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing

More information

Antares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS. Paul

Antares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS. Paul Antares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS Paul Antares Mission: To develop and commercialize self-administered parenteral medicines

More information

Press release Regulated information

Press release Regulated information IBA TRADING UPDATE - THIRD QUARTER 2014 Louvain-La-Neuve, Belgium, 13 November 2014 - IBA (Ion Beam Applications S.A., EURONEXT), the world s leading provider of proton therapy solutions for the treatment

More information

Prescription Plan FAQ s

Prescription Plan FAQ s Prescription Plan FAQ s What is a specialty medication? Specialty medication is the term used to describe certain medications and a set of services designed to meet the particular needs of people who take

More information

Global Multiple Sclerosis Market: Trends and Opportunities (2013-18)

Global Multiple Sclerosis Market: Trends and Opportunities (2013-18) Global Multiple Sclerosis Market: Trends and Opportunities (2013-18) Scope of the Report The report titled Global Multiple Sclerosis Market: Trends & Opportunities (2013-18) provides an insight into the

More information

Can India be the Leader in Global Generics. Rtn. J. Jayaseelan.,B.Pharm., M.B.A., Managing Director

Can India be the Leader in Global Generics. Rtn. J. Jayaseelan.,B.Pharm., M.B.A., Managing Director Can India be the Leader in Global Generics Rtn. J. Jayaseelan.,B.Pharm., M.B.A., Managing Director Indian Pharma Industry Before 1970 Depending on MNC from USA and Europe for supply of Medicines Hardly

More information

NYSE MKT: AXN. Pain Management, Psychiatric Treatment, Addiction Treatment, Weight Loss Treatment Narcotic Pharmaceuticals

NYSE MKT: AXN. Pain Management, Psychiatric Treatment, Addiction Treatment, Weight Loss Treatment Narcotic Pharmaceuticals Aoxing Pharmaceutical Company, Inc. NYSE MKT: AXN Pain Management, Psychiatric Treatment, Addiction Treatment, Weight Loss Treatment Narcotic Pharmaceuticals State Designated Narcotics Manufacturer Forward

More information

PHARMACEUTICAL MANAGEMENT PROCEDURES

PHARMACEUTICAL MANAGEMENT PROCEDURES PHARMACEUTICAL MANAGEMENT PROCEDURES THE FORMULARY The purpose of Coventry Health Care s formulary is to encourage use of the most cost-effective drugs. The formulary is necessary because the cost of prescription

More information

NEW CHEMICAL ENTITIES

NEW CHEMICAL ENTITIES NEW CHEMICAL ENTITIES PIONEERING PARTNER FOR PEPTIDES With more than 40 years of expertise in peptide synthesis, a track record in process development, large-scale manufacturing and outstanding product

More information

Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights. October 27, 2015

Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights. October 27, 2015 Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights October 27, 2015 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA This presentation of Merck & Co., Inc.,

More information

NOVARTIS AG (Exact name of the registrant as specified in its charter)

NOVARTIS AG (Exact name of the registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT NOVARTIS AG (Exact name of the registrant as specified in its charter) Switzerland 1-15024

More information